Menin as a hub controlling mixed lineage leukemia

BioEssays

Volumn 34, Issue 9, 2012, Pages 771-780

  Thiel, Austin T ^a   Huang, Jing ^b   Lei, Ming ^b   Hua, Xianxin ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Chromatin; Leukemia; Menin; MLL; Therapy

Indexed keywords

HYBRID PROTEIN; METHIONINE; NUCLEAR PROTEIN; SCAFFOLD PROTEIN; WNT PROTEIN;

GENE EXPRESSION; GENE TARGETING; HUMAN; LEUKEMIA; LEUKEMOGENESIS; MIXED LINEAGE LEUKEMIA; NONHUMAN; PROTEIN PROTEIN INTERACTION; REVIEW; WILD TYPE;

ACETYLATION; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONES; HOMEODOMAIN PROTEINS; HUMANS; LEUKEMIA, BIPHENOTYPIC, ACUTE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; PROTEIN INTERACTION MAPPING; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; WNT SIGNALING PATHWAY;

EID: 84865163252     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201200007     Document Type: Review

References (85)

1. Meyer C, Kowarz E, Hofmann J, Renneville A, et al. 2009. New insights to the MLL recombinome of acute leukemias. Leukemia 23: 1490-9.
2. Daser A, Rabbitts TH. 2004. Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis. Genes Dev 18: 965-74.
3. Holleman A, Cheok MH, den Boer ML, Yang W, et al. 2004. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 351: 533-42.
4. Liu H, Cheng EH, Hsieh JJ. 2009. MLL fusions: pathways to leukemia. Cancer Biol Ther 8: 1204-11.
5. Hsieh JJ, Ernst P, Erdjument-Bromage H, Tempst P, et al. 2003. Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization. Mol Cell Biol 23: 186-94.
6. Yokoyama A, Cleary ML. 2008. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 14: 36-46.
7. Jin S, Zhao H, Yi Y, Nakata Y, et al. 2010. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. J Clin Invest 120: 593-606.
8. Milne TA, Kim J, Wang GG, Stadler SC, et al. 2010. Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol Cell 38: 853-63.
9. Chen YX, Yan J, Keeshan K, Tubbs AT, et al. 2006. The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. Proc Natl Acad Sci USA 103: 1018-23.
10. Dou Y, Milne TA, Ruthenburg AJ, Lee S, et al. 2006. Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat Struct Mol Biol 13: 713-9.
11. Nakamura T, Mori T, Tada S, Krajewski W, et al. 2002. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell 10: 1119-28.
12. Terranova R, Agherbi H, Boned A, Meresse S, et al. 2006. Histone and DNA methylation defects at Hox genes in mice expressing a SET domain-truncated form of Mll. Proc Natl Acad Sci USA 103: 6629-34.
13. Pineault N, Helgason CD, Lawrence HJ, Humphries RK. 2002. Differential expression of Hox, Meis1, and Pbx1 genes in primitive cells throughout murine hematopoietic ontogeny. Exp Hematol 30: 49-57.
14. Maillard I, Chen YX, Friedman A, Yang Y, et al. 2009. Menin regulates the function of hematopoietic stem cells and lymphoid progenitors. Blood 113: 1661-9.
15. Ayton PM, Cleary ML. 2003. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 17: 2298-307.
16. Zeisig BB, Milne T, Garcia-Cuellar MP, Schreiner S, et al. 2004. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol 24: 617-28.
17. Kroon E, Krosl J, Thorsteinsdottir U, Baban S, et al. 1998. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J 17: 3714-25.
18. Thiel AT, Blessington P, Zou T, Feather D, et al. 2010. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell 17: 148-59.
19. Muntean AG, Hess JL. 2012. The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol 7: 283-301.
20. Krivtsov AV, Armstrong SA. 2007. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 7: 823-33.
21. Smith E, Lin C, Shilatifard A. 2011. The super elongation complex (SEC) and MLL in development and disease. Genes Dev 25: 661-72.
22. Nguyen AT, Zhang Y. 2011. The diverse functions of Dot1 and H3K79 methylation. Genes Dev 25: 1345-58.
23. Marschalek R. 2010. Mixed lineage leukemia: roles in human malignancies and potential therapy. FEBS J 277: 1822-31.
24. Wei J, Wunderlich M, Fox C, Alvarez S, et al. 2008. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell 13: 483-95.
25. Lavau C, Szilvassy SJ, Slany R, Cleary ML. 1997. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J 16: 4226-37.
26. So CW, Karsunky H, Wong P, Weissman IL, et al. 2004. Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9. Blood 103: 3192-9.
27. Bitoun E, Oliver PL, Davies KE. 2007. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet 16: 92-106.
28. Mohan M, Herz HM, Takahashi YH, Lin C, et al. 2010. Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev 24: 574-89.
29. Steger DJ, Lefterova MI, Ying L, Stonestrom AJ, et al. 2008. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol Cell Biol 28: 2825-39.
30. Okada Y, Feng Q, Lin Y, Jiang Q, et al. 2005. hDOT1L links histone methylation to leukemogenesis. Cell 121: 167-78.
31. DiMartino JF, Ayton PM, Chen EH, Naftzger CC, et al. 2002. The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10. Blood 99: 3780-5.
32. Nguyen AT, Taranova O, He J, Zhang Y. 2011. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood 117: 6912-22.
33. Chang MJ, Wu H, Achille NJ, Reisenauer MR, et al. 2010. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res 70: 10234-42.
34. Jo SY, Granowicz EM, Maillard I, Thomas D, et al. 2011. Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood 117: 4759-68.
35. Bernt KM, Zhu N, Sinha AU, Vempati S, et al. 2011. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20: 66-78.
36. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, et al. 2011. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20: 53-65.
37. Yokoyama A, Lin M, Naresh A, Kitabayashi I, et al. 2010. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 17: 198-212.
38. Krivtsov AV, Feng Z, Lemieux ME, Faber J, et al. 2008. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 14: 355-68.
39. Liao SM, Zhang J, Jeffery DA, Koleske AJ, et al. 1995. A kinase-cyclin pair in the RNA polymerase II holoenzyme. Nature 374: 193-6.
40. Dahmus ME. 1996. Reversible phosphorylation of the C-terminal domain of RNA polymerase II. J Biol Chem 271: 19009-12.
41. Muse GW, Gilchrist DA, Nechaev S, Shah R, et al. 2007. RNA polymerase is poised for activation across the genome. Nat Genet 39: 1507-11.
42. Peterlin BM, Price DH. 2006. Controlling the elongation phase of transcription with P-TEFb. Mol Cell 23: 297-305.
43. Mueller D, Garcia-Cuellar MP, Bach C, Buhl S, et al. 2009. Misguided transcriptional elongation causes mixed lineage leukemia. PLoS Biol 7: e1000249.
44. Wang QF, Wu G, Mi S, He F, et al. 2011. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood 117: 6895-905.
45. Chang PY, Hom RA, Musselman CA, Zhu L, et al. 2010. Binding of the MLL PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription. J Mol Biol 400: 137-44.
46. Wang Z, Song J, Milne TA, Wang GG, et al. 2010. Pro isomerization in MLL1 PHD3-bromo cassette connects H3K4me readout to CyP33 and HDAC-mediated repression. Cell 141: 1183-94.
47. Chen J, Santillan DA, Koonce M, Wei W, et al. 2008. Loss of MLL PHD finger 3 is necessary for MLL-ENL-induced hematopoietic stem cell immortalization. Cancer Res 68: 6199-207.
48. Wysocka J, Swigut T, Xiao H, Milne TA, et al. 2006. A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature 442: 86-90.
49. Ruthenburg AJ, Li H, Milne TA, Dewell S, et al. 2011. Recognition of a mononucleosomal histone modification pattern by BPTF via multivalent interactions. Cell 145: 692-706.
50. Li H, Ilin S, Wang W, Duncan EM, et al. 2006. Molecular basis for site-specific read-out of histone H3K4me3 by the BPTF PHD finger of NURF. Nature 442: 91-5.
51. Sims RJ III, Millhouse S, Chen CF, Lewis BA, et al. 2007. Recognition of trimethylated histone H3 lysine 4 facilitates the recruitment of transcription postinitiation factors and pre-mRNA splicing. Mol Cell 28: 665-76.
52. Ernst P, Wang J, Huang M, Goodman RH, et al. 2001. MLL and CREB bind cooperatively to the nuclear coactivator CREB-binding protein. Mol Cell Biol 21: 2249-58.
53. Dou Y, Milne TA, Tackett AJ, Smith ER, et al. 2005. Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell 121: 873-85.
54. Wang J, Iwasaki H, Krivtsov A, Febbo PG, et al. 2005. Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J 24: 368-81.
55. Dey A, Chitsaz F, Abbasi A, Misteli T, et al. 2003. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc Natl Acad Sci USA 100: 8758-63.
56. Yang Z, Yik JH, Chen R, He N, et al. 2005. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell 19: 535-45.
57. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, et al. 2011. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478: 529-33.
58. Muntean AG, Tan J, Sitwala K, Huang Y, et al. 2010. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell 17: 609-21.
59. Caslini C, Yang Z, El-Osta M, Milne TA, et al. 2007. Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res 67: 7275-83.
60. Grembecka J, He S, Shi A, Purohit T, et al. 2012. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol 8: 277-84.
61. Yokoyama A, Wang Z, Wysocka J, Sanyal M, et al. 2004. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol 24: 5639-49.
62. Huang J, Gurung B, Wan B, Matkar S, et al. 2012. The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature 482: 542-6.
63. Murai MJ, Chruszcz M, Reddy G, Grembecka J, et al. 2011. Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein. J Biol Chem 286: 31742-8.
64. Ayton PM, Chen EH, Cleary ML. 2004. Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein. Mol Cell Biol 24: 10470-8.
65. Allen MD, Grummitt CG, Hilcenko C, Min SY, et al. 2006. Solution structure of the nonmethyl-CpG-binding CXXC domain of the leukaemia-associated MLL histone methyltransferase. EMBO J 25: 4503-12.
66. Cierpicki T, Risner LE, Grembecka J, Lukasik SM, et al. 2010. Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia. Nat Struct Mol Biol 17: 62-8.
67. He H, Hua X, Yan J. 2011. Epigenetic regulations in hematopoietic Hox code. Oncogene 30: 379-88.
68. Faber J, Krivtsov AV, Stubbs MC, Wright R, et al. 2009. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 113: 2375-85.
69. Arai S, Yoshimi A, Shimabe M, Ichikawa M, et al. 2011. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood 117: 6304-14.
70. Peifer M, Sweeton D, Casey M, Wieschaus E. 1994. wingless signal and Zeste-white 3 kinase trigger opposing changes in the intracellular distribution of Armadillo. Development 120: 369-80.
71. Orford K, Crockett C, Jensen JP, Weissman AM, et al. 1997. Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J Biol Chem 272: 24735-8.
72. Wang Z, Smith KS, Murphy M, Piloto O, et al. 2008. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 455: 1205-9.
73. Wang Z, Iwasaki M, Ficara F, Lin C, et al. 2010. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell 17: 597-608.
74. Yeung J, Esposito MT, Gandillet A, Zeisig BB, et al. 2010. Beta-catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 18: 606-18.
75. Wang Y, Krivtsov AV, Sinha AU, North TE, et al. 2010. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 327: 1650-3.
76. Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, et al. 2011. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell 146: 697-708.
77. Jeannet G, Scheller M, Scarpellino L, Duboux S, et al. 2008. Long-term, multilineage hematopoiesis occurs in the combined absence of beta-catenin and gamma-catenin. Blood 111: 142-9.
78. Goessling W, North TE, Loewer S, Lord AM, et al. 2009. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 136: 1136-47.
79. Karp JE, Smith BD, Resar LS, Greer JM, et al. 2011. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood 117: 3302-10.
80. Byrd JC, Lin TS, Dalton JT, Wu D, et al. 2007. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109: 399-404.
81. Zuber J, Shi J, Wang E, Rappaport AR, et al. 2011. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524-8.
82. Filippakopoulos P, Qi J, Picaud S, Shen Y, et al. 2010. Selective inhibition of BET bromodomains. Nature 468: 1067-73.
83. McMahon KA, Hiew SY, Hadjur S, Veiga-Fernandes H, et al. 2007. Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal. Cell Stem Cell 1: 338-45.
84. Jude CD, Climer L, Xu D, Artinger E, et al. 2007. Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell 1: 324-37.
85. Gan T, Jude CD, Zaffuto K, Ernst P. 2010. Developmentally induced Mll1 loss reveals defects in postnatal haematopoiesis. Leukemia 24: 1732-41.